Production Of Plasma Proteins For Therapeutic Use

Contributors mostly from drug companies but also some university and government laboratories explore the biotechnology of proteins in human blood plasma. The material is for people with a scientific, technical, research, clinical, or commercial interest in therapeutic products derived from blood plasma. Most of the book is devoted to specific plasma proteins for specific therapeutic use, but other sections consider plasma factionation, pathogen safety in plasma products, the pharmaceutical environment applied to plasma fractionation, and the market for plasma products and the economics of fractionation. Annotation c2013 Book News, Inc., Portland, OR (booknews.com)

JOSEPH BERTOLINI, BSc (HONS.), MSc, PhD, is R&D Manager at CSL Bioplasma where he has been closely involved in the technical development and improvement of immunoglobulin and albumin products. He is active in national and international conferences and industry organizations and is a strong advocate for the advancement of bioprocessing.

NEIL GOSS, BSc (HONS.), PhD, is Executive Director at Further Options Pty Ltd., a consulting company specializing in biotechnology and the plasma fractionation industry. He was previously Director of R&D, CSL Bioplasma and is the founding organizer for both the Plasma Product Biotechnology Meeting series and the BioProcessing Network.

JOHN CURLING, BSc, is a consultant in bioseparations and protein purification whose clients have included numerous biopharmaceutical, biotechnology, and vendor companies. He pioneered the development of chromatographic methods of plasma fractionation and was the President of the Process Separation Division of Pharmacia. He has acted as an advisor to the World Health Organization.